![Todd A. Huffman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Todd A. Huffman
Founder at Padlock Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Gilman | M | 69 |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 years |
Kerri Mowen | M | - |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 years |
James R. Andrews | M | 82 |
The University of Virginia School of Medicine
| - |
Elizabeth L. Anderson | M | 83 |
University of Virginia
| 19 years |
David Grainger | M | 58 |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
Kevin R. Lynch | M | - |
The University of Virginia School of Medicine
| - |
Roel Bulthuis | M | - |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 years |
Michael Gladstone | M | 37 |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
Marian Nakada | M | - |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
Paul Thompson | M | - |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
Rab Prinjha | M | - |
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
Nathan Fountain | M | 61 |
The University of Virginia School of Medicine
| - |
Linda Duska | F | - |
The University of Virginia School of Medicine
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ryan Berg | M | - |
University of Virginia
| 10 years |
Adam Fassnacht | M | - |
University of Virginia
| 6 years |
Rahul Gorawara | M | - |
University of Virginia
| 5 years |
Zachary Bratun Glennon | M | - |
University of Virginia
| 4 years |
Alexander T. Seals | M | - |
University of Virginia
| 5 years |
Francis Teo | M | - |
University of Virginia
| 6 years |
Edward Shuman | M | - |
University of Virginia
| 9 years |
Scott B Crenshaw | M | - |
University of Virginia
| 6 years |
Kevin Matthew Mixon | M | - |
University of Virginia
| 4 years |
Howard Hechler | M | - |
University of Virginia
| 4 years |
Max Leykin | M | - |
University of Virginia
| 5 years |
Chris Carroll | M | - |
University of Virginia
| 4 years |
Linda S. Tansik | F | - |
RCT BioVentures
![]() RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | 26 years |
Nitin Chandra | M | - |
University of Virginia
| 9 years |
McGavock Dickinson Dunbar | M | - |
University of Virginia
| 4 years |
Kristina Wilmer | F | - |
University of Virginia
| 7 years |
Ryan Gurney | M | - |
University of Virginia
| 4 years |
Brock Saunders | M | - |
University of Virginia
| 4 years |
William DeVar | M | - |
University of Virginia
| 4 years |
Nick Harris | M | - |
University of Virginia
| 4 years |
Alan Lawrence Broderick | M | - |
University of Virginia
| 4 years |
Tracy Schwartz-Ward | F | - |
University of Virginia
| 4 years |
Richard Middleton Williamson | M | - |
University of Virginia
| 4 years |
Erhan Artuc | M | - |
University of Virginia
| 3 years |
Viraj Didwania | M | - |
University of Virginia
| 4 years |
Chen Feng Song | M | 42 |
University of Virginia
| 4 years |
David Seaman | M | - |
University of Virginia
| 10 years |
Zachary F. Hill | M | - |
University of Virginia
| 4 years |
Ethan James Appleby | M | - |
University of Virginia
| 4 years |
Harrison Segall | M | - |
University of Virginia
| 4 years |
William Flood | M | - |
University of Virginia
| 3 years |
Brian Fairbank | M | - |
University of Virginia
| 4 years |
Tarapore Shahrukh | M | - |
University of Virginia
| 2 years |
Geoffrey Miles | M | - |
University of Virginia
| 4 years |
Diane Banta | F | - |
University of Virginia
| 4 years |
Hanny Akl | M | - |
University of Virginia
| 1 years |
Christos Tsentas | M | 37 |
University of Virginia
| 4 years |
Thaddeus Darden | M | 37 |
University of Virginia
| 4 years |
Dave Olsen | M | - |
University of Virginia
| 1 years |
Ryan Grammer | M | - |
University of Virginia
| 4 years |
Rachel Kropa | F | - |
University of Virginia
| 4 years |
Ed Cao | M | - |
University of Virginia
| 4 years |
Lauren Nanna | F | - |
University of Virginia
| 4 years |
James Edward Bogart | M | - |
University of Virginia
| 4 years |
Jackie Dunklau | F | - |
University of Virginia
| 4 years |
Francis Nathaniel Gotianun | M | 40 |
University of Virginia
| 4 years |
Mesh Lakhani | M | - |
University of Virginia
| 4 years |
Srikripa Devarakonda | M | - |
University of Virginia
| 6 years |
Jed Leidheiser | M | - |
University of Virginia
| 4 years |
Guido DeAscanis | M | - |
University of Virginia
| 2 years |
Jonathan Chou | M | - |
University of Virginia
| 4 years |
Seanan Maranzano | M | - |
University of Virginia
| 4 years |
Tyler Walk | M | - |
University of Virginia
| 4 years |
Jaime Forsyth | F | - |
University of Virginia
| 4 years |
Christopher C. Green | M | - |
University of Virginia
| 3 years |
Peter Chidyllo | M | - |
University of Virginia
| 4 years |
Daniel Lawrence | M | - |
University of Virginia
| 4 years |
Scott B. Luftglass | M | - |
University of Virginia
| 3 years |
Louise M. Bald | F | - |
University of Virginia
| 4 years |
Chad Ellis | M | - |
University of Virginia
| 4 years |
John L. Gainer | M | 85 |
University of Virginia
| 39 years |
David Lonergan | M | - |
RCT BioVentures
![]() RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | 2 years |
Cody Nystrom | F | - |
University of Virginia
| 4 years |
Philip Giampietro | M | - |
University of Virginia
| 4 years |
Michael F. Farah | M | - |
University of Virginia
| 4 years |
Matthew Mariner | M | - |
University of Virginia
| 4 years |
Kenneth Rollins | M | - |
University of Virginia
| 3 years |
Rosemary Liu | F | - |
University of Virginia
| 4 years |
Zhi Xiong Yan | M | 53 |
University of Virginia
| 2 years |
Noah Charles Perry Greenbaum | M | - |
University of Virginia
| 4 years |
David Proman | M | 41 |
University of Virginia
| 4 years |
Kenneth Suggett George | M | - |
University of Virginia
| 4 years |
Brad Sullivan | M | - |
University of Virginia
| 2 years |
Bradford James Manning | M | - |
University of Virginia
| 4 years |
Evan Ufer | M | - |
University of Virginia
| 4 years |
Ross Baird | M | - |
University of Virginia
| 4 years |
Michael Koban | M | - |
University of Virginia
| 4 years |
Brian Welsh | M | - |
University of Virginia
| 4 years |
James Aldige | M | - |
University of Virginia
| 4 years |
Ali Houshmand | M | - |
University of Virginia
| 2 years |
Daniel Hayden Saunders | M | - |
University of Virginia
| 4 years |
Yumee Song | F | - |
University of Virginia
| 4 years |
Teddy Lamade | M | - |
University of Virginia
| 4 years |
Justin P. Lux | M | - |
University of Virginia
| 4 years |
Pike Howard | M | - |
University of Virginia
| 4 years |
Jagjit Idnani | M | - |
University of Virginia
| 4 years |
Louis Matthews | M | - |
University of Virginia
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 96 | 96.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Todd A. Huffman
- Personal Network